Posted by Michael Wonder on 22 Aug 2022
Hansa Biopharma and Medison Pharma announce positive reimbursement decision in Poland for Idefirix in highly sensitised kidney transplant patients
22 August 2022 - Reimbursement follows the inclusion of Idefirix on the shortlist for exceptional innovative treatments with special funding.
Hansa Biopharma and its partner Medison Pharma today announced that the Polish Ministry of Health has agreed to include Idefirix on its reimbursement list for desensitisation of highly sensitised patients prior to kidney transplantation.
